Safety and immunogenicity of a bivalent norovirus vaccine candidate in infants from 6 weeks to 5 months of age: A phase 2, randomized, double-blind trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Human Vaccines & Immunotherapeutics

Topics

Medicine

Immunology

Pathology

Internal Medicine

Infectious Diseases

Show all topics

DOI

10.1080/21645515.2025.2450878

License

CC-BY-NC